Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

Consortium for TB Biomarkers (CTB2) Biorepository

The Consortium for TB Biomarkers (CTB2) has created a collaborative biobank in order to accelerate the development of new drugs and treatments for tuberculosis by validating and exploring biomarkers of response to TB drug treatments.  The biobank will ultimately house biospecimens from 1000 adult patients in long-term storage for use by the TB research community.

Main Areas of Focus

  • To establish a robust biorepository to support and expedite the discovery and qualification of biomarkers of TB drug effect

Tools

Sample repository includes:

  • RNA from whole blood
  • Whole blood
  • Plasma
  • Urine
  • Sputum 

Collaboration Opportunities

  • This resource collects and stores biologic samples (blood, urine, and sputum) via donation from patients in existing clinical studies or programs who are undergoing treatment for tuberculosis. 

Who Can Use This Resource

  • The Biorepository will award biospecimens to research which is deemed to have the greatest opportunity to achieve CTB2’s goal of accelerating the development of biomarkers of TB drug effect.

How To Get Started

  • Contact the repository before applying
Content last reviewed on November 17, 2017